Order byBest matchMost fresh

Eli Lilly, Hims

Digest more
Top News
Impacts
Seeking Alpha |
Compounding pharmacies were legally permitted to make compounded versions of tirzepatide while the drug was in shortage.
Business Insider |
Moreover, Bank of America also published bearish guidance, given that the company is expected to stop compounded semaglutide drug sales by May 22nd.

Read more on News Digest

Eli Lilly takes actions to stop compounders from making its weight loss med
Eli Lilly ( NYSE: LLY) on Tuesday will file lawsuits against two companies that the drug giant is accusing of mass compounding its blockbuster GLP-1/GIP receptor agonist tirzepatide. Tirzepatide is the active ingredient in Zepbound for weight loss and Mounjaro for type 2 diabetes.
DTC obesity med market heats up: Eli Lilly taps knownwell, Hims & Hers adds new weight loss meds to platform
Hims & Hers is expanding access to Eli Lilly's branded weight loss drug Zepbound and diabetes drug Mounjaro as well as generics of Novo Nordisk's diabetes drug liraglutide through its weight loss platform.
Hims & Hers Stock Surges as Telehealth Platform Adds Eli Lilly Weight-Loss Drugs
Hims & Hers Health shares jumped Tuesday as the company added Eli Lilly’s weight-loss drug Zepbound and diabetes treatment Mounjaro to its telehealth platform.
‘Too Hot to Handle,’ Analyst Warning on Hims & Hers Health Stock (HIMS)
Telehealth platform Hims & Hers Health, Inc. (HIMS), which connects consumers to healthcare professionals, is at a crossroads. With sales
Zepbound Now Available Through Hims & Hers
Zepbound is made by drugmaker Eli Lilly. While Hims & Hers offers it for $1,899 per month, Lilly said the price on its own LillyDirect platform starts at $349 for self-paying customers. With insurance,
Why April Could Be a Huge Month for Eli Lilly Stock
A key drug that investors are going to be following this year is orforglipron, a once-daily pill that Eli Lilly is developing for weight loss and other indications. The early data has been encouraging,
Eli Lilly sues two pharmacies making copycat Zepbound, Mounjaro
Eli Lilly is suing Strive Pharmacy and Empower Pharmacy for compounding tirzepatide, the active ingredient in Zepbound and Mounjaro.
inews.co.uk on MSN2h
Why the viral £50 Mounjaro ‘dose hack’ could be dangerous
Mounjaro weight-loss injection pens should contain four doses, but some users are managing to get a fifth dose out of the devices. Experts are warning against this
Eli Lilly sues Strive and Empower as FDA lifts tirzepatide shortage status
Eli Lilly sues two compounders over tirzepatide after FDA lifts Zepbound, Mounjaro shortage status in key GLP-1 legal test.
Eli Lilly Vs. Novo Nordisk: Which Is The Better Bargain For Investors
Eli Lilly and Novo Nordisk occupy leading positions in the obesity and diabetes markets. Find out which is the better bargain for investors.
Where Will Eli Lilly Be in 1 Year?
Lately, however, Eli Lilly's stock has cooled. Shares have been essentially flat since July 2024. The market for GLP-1 agonists could be evolving, and Eli Lilly has a high-stakes opportunity to dominate it over the coming year.
Explore more
Hims & Hers to sell Lilly's weight-loss drug on its telehealth platform (April 1)
Shares of Hims & Hers closed 5.1% higher after the company said it will expand its weight-loss offerings with branded versions of Lilly's tirzepatide — the active ingredient in weight-loss drug Zepbound and diabetes medicine Mounjaro — and generics of Novo's diabetes drug,
Eli Lilly Vs. Hims & Hers In DTC Weight Loss Market? - There Is Only One Winner
Eli Lilly (LLY) leads with groundbreaking tirzepatide (Mounjaro/Zepbound), while Hims & Hers Health (HIMS) faces challenges. Find out who is the winner.
Will Weight Loss Drug, 'Mounjaro' Reduce Obesity In India? Doctor Reveals Side Effects Linked To This Treatment
India took a much-needed step in the fight against obesity and diabetes with the introduction of Mounjaro (tirzepatide), a drug developed by American pharmaceutical giant Eli Lilly and Co. Approved by the Central Drugs Standard Control Organisation (CDSCO),
Feedback